Reduced-Dose Apixaban in the Treatment of Left Ventricular Thrombus: A Report of 2 Cases
- 7 December 2022
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (2) , 517-521
Abstract
According to the American College of Cardiology and the American Heart Association, warfarin has historically been the standard of care anticoagulant for the treatment of left ventricular thrombus. The use of direct oral anticoagulants (DOACs) has become more prevalent, as they require less frequent laboratory monitoring, offer fixed-dose regimens, are associated with fewer drug-drug and drug-food interactions, and provide more favorable safety profiles when compared to warfarin. However, DOACs are not currently FDA-indicated in the treatment of left ventricular (LV) thrombus. Numerous recent studies have reported and evaluated the use of DOACs for treatment of LV thrombus. Recently, a prospective, open-label, multicenter study evaluated warfarin compared to DOACs for LV thrombus treatment. The AHA recently published a scientific statement regarding the management of patients at risk for and with left ventricular thrombus, which included DOACs as a reasonable alternative to warfarin. This report describes two patients treated with DOACs following LV thrombus diagnosis. The first case is a 71-year-old male admitted for cerebrovascular accident and non-ST-elevation myocardial infarction complicated by a LV thrombus. The second case is an 83-year-old female admitted for acute myocardial infarction complicated with an LV thrombus. Both patients were prescribed apixaban 2.5 mg twice daily. Neither patient has experienced LV thrombus or DOAC treatment related complications. This case series serves as evidence for reduced-dose DOACs as an alternative to warfarin in the treatment of LV thrombus.Keywords
This publication has 25 references indexed in Scilit:
- The role of rivaroxaban in left ventricular thrombiThe Anatolian Journal of Cardiology, 2018
- Challenges in management of left ventricular thrombusTherapeutic Advances in Cardiovascular Disease, 2017
- Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary InterventionJACC, 2015
- Duration of Dual Antiplatelet Therapy After Coronary StentingJACC, 2015
- Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trialsBMJ, 2015
- Frequency and Correlates of Early Left Ventricular Thrombus Formation Following Anterior Wall Acute Myocardial Infarction Treated With Primary Percutaneous Coronary InterventionThe American Journal of Cardiology, 2013
- Prevalence of left chamber cardiac thrombi in patients with dilated left ventricle at sinus rhythm: The role of transesophageal echocardiographyJournal of Clinical Ultrasound, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007